

Contents

Preface.....	v
Contributors.....	xi
Color Plates.....	xv

PART I: TRENDS IN PROSTATE CANCER SCREENING

1 Overview of US Prostate Cancer Trends in the Era of PSA Screening.....	3
<i>Ruth Etzioni, Roman Gulati, and Angela Mariotto</i>	
2 Trends in Prostate Cancer Screening: Overview of the UK.....	15
<i>Richard J. Bryant and Freddie C. Hamdy</i>	
3 Trends in Prostate Cancer Screening: Canada.....	23
<i>Robert K. Nam and Laurence H. Klotz</i>	
4 Trends in Prostate Cancer Screening – Overview of Europe.....	35
<i>Sanjai K. Addla and Bob Djavan</i>	

PART II: PROSTATE-SPECIFIC ANTIGEN

5 Evolution of Prostate-Specific Antigen for Screening.....	51
<i>Javier Hernandez and Edith Canby-Hagino</i>	
6 The Performance Characteristics of Prostate-Specific Antigen for Prostate Cancer Screening.....	61
<i>Ian M. Thompson, Jr. and Donna P. Ankerst</i>	
7 The Performance of PSA for Predicting Prostate Cancer After a Prior Negative Prostate Biopsy.....	71
<i>Catherine M. Tangen</i>	
8 Subfractions and Derivatives of Total Prostate-Specific Antigen in the Early Detection of Prostate Cancer.....	79
<i>Alexander Haese and Alan W. Partin</i>	
9 PSA Velocity at Presentation as a Predictor of Prostate Cancer Aggressiveness.....	97
<i>Jason A. Efstathiou and Anthony V. D’Amico</i>	

PART III: RISK ASSESSMENT FOR PROSTATE CANCER

10 Nomograms for Prostate Cancer.....	117
<i>Shahrokh F. Shariat and Michael W. Kattan</i>	

- 11 Decision Aid Criteria and Artificial Neural Networks for Optimizing Prostate Cancer Risk Prediction 181
Felix K.-H. Chun and Pierre I. Karakiewicz
- 12 Development of the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator 195
Donna P. Ankerst and Ian M. Thompson
- 13 Integration of Risk Assessment in Prostate Cancer Screening 205
Kadee E Thompson, Amanda Reed, and Dipen J Parekh
- 14 Family History of Prostate Cancer During Rapidly Increasing Incidence 213
Kari Hemminki and Justo Lorenzo Bermejo

PART IV: RECENT BIOMARKERS FOR PROSTATE CANCER

- 15 PSA Isoforms: [-2]proPSA Significant Adjunct to Free PSA 225
Jeffrey E. Tam
- 16 PCA3 233
Jack Groskopf, Jack Schalken, and Harry Rittenhouse
- 17 Transcriptional Profiling of Prostate Cancer: Biomarker Identification and Clinical Applications 243
Nigel Clegg and Peter S. Nelson
- 18 Biomarkers for Prostate Cancer Detection: Family-Based Linkage Analysis and Case-Control Association Studies 261
Joke Beuten and Teresa L Johnson-Pais
- 19 *GSTP1* Hypermethylation for Prostate Cancer Detection 279
Rui Henrique and Carmen Jerónimo
- 20 EPCA and EPCA-2 as Potential Biomarkers for Prostate Cancer Detection 289
Eddy S. Leman and Robert H. Getzenberg

PART V: DESIGN AND METHODOLOGIC CONSIDERATIONS IN BIOMARKER STUDIES

- 21 Toward a Robust System for Biomarker Triage and Validation – EDRN Experience 297
Ziding Feng, Jacob Kagan and Sudhir Srivastava
- 22 Statistical Evaluation of Markers and Risk Tools for Prostate Cancer Classification and Prediction 307
Yingye Zheng and Donna P. Ankerst
- 23 Pitfalls in Prostate Cancer Biomarker Evaluation Studies 319
Donna P. Ankerst

PART VI: BUILDING UPON RECENTLY COMPLETED AND ONGOING PROSPECTIVE TRIALS

- 24 Prostate-Specific Antigen and Its Role on the Prostate Cancer Prevention Trial 333
Catherine M. Tangen and Phyllis J. Goodman

25	The Selenium and Vitamin E Cancer Prevention Trial	349
	<i>Eric A. Klein</i>	
26	PLCO: A Randomized Controlled Screening Trial for Prostate, Lung, Colorectal, and Ovarian Cancer	361
	<i>Amanda Black, Robert L. Grubb III, and E. David Crawford</i>	
27	The European Randomized Study of Screening for Prostate Cancer (ERSPC)	373
	<i>Tineke Wolters and Fritz H. Schröder</i>	
	Index	387